妊娠期使用新冠疫苗成分及平台的安全性:快速综述
该快速系统综述评估了COVID-19疫苗及其成分和技术平台在妊娠期使用的安全性,检索至2021年2月,纳入38项研究(涉及2,398,855名孕妇和56只孕动物)。大多数研究未发现妊娠相关安全信号,仅一项初步报告被作者更正。结论支持WHO指南推荐孕妇可考虑接种COVID-19疫苗。
要点
- 大多数研究未发现COVID-19疫苗成分或平台在妊娠期使用的安全性问题。
- 仅一项关于AS03佐剂A/H1N1流感疫苗的初步报告被作者更正。
- 支持WHO指南:孕妇可考虑接种COVID-19疫苗,尤其高风险暴露或有合并症者。
核心结论
- 本快速综述未发现COVID-19疫苗或其成分/平台在妊娠期使用存在妊娠相关安全性问题的证据。
- 鉴于疫苗平台和成分的新颖性,仍需进一步数据。
- 研究结果支持当前WHO指南推荐孕妇可考虑接种COVID-19疫苗。
研究设计与样本
- 快速系统综述,检索文献数据库、COVID-19疫苗妊娠登记库及参考文献列表,从建库至2021年2月,无语言限制。
- 纳入38项临床和非临床研究,涉及2,398,855名孕妇和56只孕动物。
- 大多数研究(89%)在高收入国家进行,57%为队列研究,76%比较妊娠三个孕期疫苗暴露与无暴露。
主要发现
- 最常见的暴露为AS03佐剂(n=24,来自A/H1N1流感疫苗)和铝佐剂(n=11)。
- 仅一项研究报道了脂质纳米颗粒mRNA COVID-19疫苗的暴露。
- 除一项关于AS03佐剂A/H1N1流感疫苗的初步报告被作者更正外,所有研究均认为无安全性问题。
临床怎么用
- 孕妇可考虑接种COVID-19疫苗,尤其在高风险暴露或有增加重症风险的合并症时。
- 接种决策应结合当前WHO指南和个体风险评估。
局限性
- 大多数研究来自高收入国家,可能限制普遍性。
- 仅一项研究涉及mRNA COVID-19疫苗,数据有限。
- 部分疫苗平台和成分的新颖性意味着需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rapid assessment of COVID-19 vaccine safety during pregnancy is urgently needed. METHODS: We conducted a rapid systematic review, to evaluate the safety of COVID-19 vaccines selected by the COVID-19 Vaccines Global Access-Maternal Immunization Working Group in August 2020, including their components and their technological platforms used in other vaccines for pregnant persons. We searched literature databases, COVID-19 vaccine pregnancy registries, and explored reference lists from the inception date to February 2021 without language restriction. Pairs of reviewers independently selected studies through COVIDENCE, and performed the data extraction and the risk of bias assessment. Discrepancies were resolved by consensus. Registered on PROSPERO (CRD42021234185). RESULTS: We retrieved 6757 records and 12 COVID-19 pregnancy registries from the search strategy; 38 clinical and non-clinical studies (involving 2,398,855 pregnant persons and 56 pregnant animals) were included. Most studies (89%) were conducted in high-income countries and were cohort studies (57%). Most studies (76%) compared vaccine exposures with no exposure during the three trimesters of pregnancy. The most frequent exposure was to AS03 adjuvant, in the context of A/H1N1 pandemic influenza vaccines, (n = 24) and aluminum-based adjuvants (n = 11). Only one study reported exposure to messenger RNA in lipid nanoparticles COVID-19 vaccines. Except for one preliminary report about A/H1N1 influenza vaccination (adjuvant AS03), corrected by the authors in a more thorough analysis, all studies concluded that there were no safety concerns. CONCLUSION: This rapid review found no evidence of pregnancy-associated safety concerns of COVID-19 vaccines or of their components or platforms when used in other vaccines. However, the need for further data on several vaccine platforms and components is warranted, given their novelty. Our findings support current WHO guidelines recommending that pregnant persons may consider receiving COVID-19 vaccines, particularly if they are at high risk of exposure or have comorbidities that enhance the risk of severe disease.
引用
- Ciapponi A, Bardach A, Mazzoni A, et al. Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review. Vaccine. 2021. PMID: 34489131. doi:10.1016/j.vaccine.2021.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。